Altamira Therapeutics Ltd. Revenue And Operating Income
Altamira Therapeutics Ltd. (CYTOF) reported Revenue And Operating Income of CHF 255.59 thousand for the 12-month period ending 2023-12-31, per its 20-F/A filed 2024-04-22.
Discontinued › Income Statement › Other Income
ifrs-full:RevenueAndOperatingIncome · last filed 2024-04-22
| Period end | Revenue And Operating Income 12 month | Revenue And Operating Income 12 month as first filed |
|---|---|---|
| 2023-12-31 | 255.59K CHF 20-F/A · filed 2024-04-22 | |
| 2022-12-31 | 9.33K CHF 20-F/A · filed 2024-04-22 | 709.45K CHF 20-F · filed 2023-05-16 |
| 2021-12-31 | 214.22K CHF 20-F · filed 2023-05-16 | 460.71K CHF 20-F · filed 2022-04-12 |
| 2020-12-31 | 174.47K CHF 20-F · filed 2023-05-16 |